

an Open Access Journal by MDPI

Marine Glycosides

Guest Editors:

Prof. Dr. Thomas E Adrian

Department of Physiology,
United Arab Emirates University,
Al Ain, Abu Dhabi, United Arab
Emirates

Prof. Dr. Francisco Sarabia

Department of Organic
Chemistry, Faculty of Science,
University of Málaga, 29071
Málaga, Spain

Dr. Ivan Cheng-Sanchez

Department of Chemistry,
University of Zurich, Zurich,
Switzerland

Deadline for manuscript
submissions:

closed (31 May 2018)

Message from the Guest Editors

Dear Colleagues,

In recent years, there has been a steady increase in the publication of papers on the chemistry, biology, and potential clinical uses of marine glycosides. Glycosides have been isolated from species as diverse as algae, fungi, anthozoans, and echinoderms. Even fish of the genus *Pardachirus* produce glycosides that they use as shark repellents.


The major interest in these compounds as potential drugs stems from the broad spectrum of biological effects. They have been shown to have antimicrobial, antifungal, anti-inflammatory, immune modulatory and anticancer effects. The anticancer effects of marine glycosides include cell cycle suppression, induction of apoptosis, inhibition of migration, invasion and metastasis, as well as antiangiogenesis.

This Special Issue will cover the entire scope of marine organism-derived glycosides that are of potential value as pharmaceutical agents or leads. These include, but are not limited to, tetracyclic triterpene glycosides; other triterpene glycosides; steroid glycosides; and glycosides of non-isoprenoid aglycones.



mdpi.com/si/9434

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

Contact Us

Marine Drugs Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
X@Marine_Drugs